ARTICLE | Clinical News
Subgam-VF: Phase III started
September 28, 2015 7:00 AM UTC
Bio Products began the open-label, U.S. Phase III SCIG03 trial to evaluate weekly subcutaneous Subgam-VF for up to 26 weeks in about 35 patients. ...
Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
Bio Products began the open-label, U.S. Phase III SCIG03 trial to evaluate weekly subcutaneous Subgam-VF for up to 26 weeks in about 35 patients. ...